Inovio’s Co-Founder and Chair of its Scientific Advisory Board Selected as a Top 20 Translational Researcher
November 21 2016 - 8:00AM
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that Dr.
David B. Weiner, its co-founder, board member and chair of its
scientific advisory board, has been selected as a “Top 20
Translational Researcher” for the year 2015 by the editors of
Nature Biotechnology magazine. The selection is based on the number
of medical innovations that led to patents a researcher was granted
in a calendar year. The designation “translational researcher”
refers to basic research that can move from the lab bench to become
patented medicine.
Dr. Weiner’s patented innovations relate to
advancing the field of DNA-based immunotherapies targeting
challenging infectious diseases and cancers. Over his career he
holds more than 100 issued and pending U.S. patents. From 1986
until 2015, Dr. Weiner’s lab was at the University of Pennsylvania,
Perelman School of Medicine. In 2016, Dr. Weiner joined The Wistar
Institute, the nation’s first independent biomedical research
institute, an NCI-designated Cancer Center, and an international
leader in cancer, immunology and infectious disease research, as
Executive Vice President, Director of its Vaccine Center and the W.
W. Smith Charitable Trust Endowed Professorship in Cancer
Research.
Dr. J. Joseph Kim, Inovio's President and CEO,
said, "This award acknowledges David’s innovation and commitment to
creating tomorrow’s medicines with a revolutionary technology,
DNA-based immunotherapies and vaccines, which Inovio is developing
in early and late-stage clinical trials. While I can say I am
personally proud of my association with Dr. Weiner, which is now
decades long, I can also say that we at Inovio as a team have
tremendous respect and appreciation for his innovation and
dedication to this field and congratulate him on this award.”
About Dr. David B. Weiner
Dr. Weiner is a world-renowned leader in
immunology as well as gene vaccines and immunotherapy. In
scientific circles he is known as the “father of DNA vaccines.” He
has more than 350 peer-reviewed publications in scientific
journals, including mainstream publications such as Scientific
American, and has been designated by the Institute for Scientific
Information as one of the top-cited scientists in the world. An
inventor of more than 100 issued and pending U.S. patents, Dr.
Weiner has received numerous honors including election as a fellow
to the American Association for the Advancement of Science in 2011
and the International Society for Vaccines in 2012. He was the
recipient of the NIH Director’s Transformative Research Award and
received the Vaccine Industry Excellence Award for Best Academic
Research Team in 2015 at the World Vaccine Congress. Dr. Weiner was
honored with the prestigious Hilleman Lectureship in 2015 at the
Children’s Hospital of Philadelphia Grand Rounds session and
received a Stone Family Award from Abramson Cancer Center for his
groundbreaking work on DNA vaccines for cancer immune therapy.
David Weiner holds a Ph.D. in developmental
biology from the University of Cincinnati College of Medicine, an
M.S. in biology from the University of Cincinnati, and a B.S. in
biology from SUNY at Stony Brook in Stony Brook, N.Y.
About Inovio Pharmaceuticals,
Inc.
Inovio is taking immunotherapy to the next level
in the fight against cancer and infectious diseases. We are the
only immunotherapy company that has reported generating T cells in
vivo in high quantity that are fully functional and whose killing
capacity correlates with relevant clinical outcomes with a
favorable safety profile. With an expanding portfolio of immune
therapies, the company is advancing a growing preclinical and
clinical stage product pipeline. Partners and collaborators include
MedImmune, The Wistar Institute, University of Pennsylvania, DARPA,
GeneOne Life Science, Plumbline Life Sciences, Drexel University,
NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S.
Military HIV Research Program, and Laval University. For more
information, visit www.inovio.com.
This press release contains certain
forward-looking statements relating to our business, including our
plans to develop electroporation-based drug and gene delivery
technologies and DNA vaccines, our expectations regarding our
research and development programs and our capital resources. Actual
events or results may differ from the expectations set forth herein
as a result of a number of factors, including uncertainties
inherent in pre-clinical studies, clinical trials and product
development programs, the availability of funding to support
continuing research and studies in an effort to prove safety and
efficacy of electroporation technology as a delivery mechanism or
develop viable DNA vaccines, our ability to support our broad
pipeline of SynCon® active immunotherapy and vaccine products, the
ability of our collaborators to attain development and commercial
milestones for products we license and product sales that will
enable us to receive future payments and royalties, the adequacy of
our capital resources, the availability or potential availability
of alternative therapies or treatments for the conditions targeted
by the company or its collaborators, including alternatives that
may be more efficacious or cost effective than any therapy or
treatment that the company and its collaborators hope to develop,
issues involving product liability, issues involving patents and
whether they or licenses to them will provide the company with
meaningful protection from others using the covered technologies,
whether such proprietary rights are enforceable or defensible or
infringe or allegedly infringe on rights of others or can withstand
claims of invalidity and whether the company can finance or devote
other significant resources that may be necessary to prosecute,
protect or defend them, the level of corporate expenditures,
assessments of the company's technology by potential corporate or
other partners or collaborators, capital market conditions, the
impact of government healthcare proposals and other factors set
forth in our Annual Report on Form 10-K for the year ended December
31, 2015, our Form 10-Q for the quarter ended September 30,
2016, and other regulatory filings from time to time. There
can be no assurance that any product in Inovio's pipeline will be
successfully developed or manufactured, that final results of
clinical studies will be supportive of regulatory approvals
required to market licensed products, or that any of the
forward-looking information provided herein will be proven
accurate.
CONTACTS:
Investors: Bernie Hertel, Inovio Pharmaceuticals, 858-410-3101, bhertel@inovio.com
Media: Jeff Richardson, Inovio Pharmaceuticals, 267-440-4211, jrichardson@inovio.com
Inovio Pharmaceuticals (NASDAQ:INO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Inovio Pharmaceuticals (NASDAQ:INO)
Historical Stock Chart
From Apr 2023 to Apr 2024